155 related articles for article (PubMed ID: 22785024)
1. Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia.
Inagaki M; Nakagawa-Toyama Y; Nishida M; Nakatani K; Nakaoka H; Kawase M; Kawase R; Tsubakio-Yamamoto K; Masuda D; Ohama T; Matsuyama A; Ishigami M; Komuro I; Yamashita S
J Atheroscler Thromb; 2012; 19(7):643-56. PubMed ID: 22785024
[TBL] [Abstract][Full Text] [Related]
2. Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles.
Adlouni A; El Messal M; Saïle R; Parra H; Fruchart J; Ghalim N
Atherosclerosis; 2000 Oct; 152(2):433-40. PubMed ID: 10998472
[TBL] [Abstract][Full Text] [Related]
3. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
4. [Probucol treatment of hyperlipidemia].
Koizumi J
Nihon Rinsho; 1994 Dec; 52(12):3279-84. PubMed ID: 7853723
[TBL] [Abstract][Full Text] [Related]
5. Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency.
Noto H; Kawamura M; Hashimoto Y; Satoh H; Hara M; Iso-o N; Togo M; Kimura S; Tsukamoto K
Atherosclerosis; 2003 Nov; 171(1):131-6. PubMed ID: 14642415
[TBL] [Abstract][Full Text] [Related]
6. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
Matsuzawa Y; Yamashita S; Funahashi T; Yamamoto A; Tarui S
Am J Cardiol; 1988 Jul; 62(3):66B-72B. PubMed ID: 3394656
[TBL] [Abstract][Full Text] [Related]
7. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia.
Karabina SA; Elisaf M; Bairaktari E; Tzallas C; Siamopoulos KC; Tselepis AD
Eur J Clin Invest; 1997 Jul; 27(7):595-602. PubMed ID: 9263748
[TBL] [Abstract][Full Text] [Related]
8. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients.
Tomás M; Sentí M; García-Faria F; Vila J; Torrents A; Covas M; Marrugat J
Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2113-9. PubMed ID: 10978257
[TBL] [Abstract][Full Text] [Related]
9. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits.
Hong SC; Zhao SP; Wu ZH
J Cardiovasc Pharmacol; 2006 Jan; 47(1):77-81. PubMed ID: 16424789
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein fractions and receptors: a role for probucol?
Bilheimer DW
Am J Cardiol; 1986 Jun; 57(16):7H-15H. PubMed ID: 3637051
[TBL] [Abstract][Full Text] [Related]
11. Where are we with probucol: a new life for an old drug?
Yamashita S; Matsuzawa Y
Atherosclerosis; 2009 Nov; 207(1):16-23. PubMed ID: 19457483
[TBL] [Abstract][Full Text] [Related]
12. Clinical study on the effect of simvastatin on paraoxonase activity.
Muacević-Katanec D; Bradamante V; Poljicanin T; Reiner Z; Babić Z; Simeon-Rudolf V; Katanec D
Arzneimittelforschung; 2007; 57(10):647-53. PubMed ID: 18074758
[TBL] [Abstract][Full Text] [Related]
13. Effects of probucol on xanthomata regression in familial hypercholesterolemia.
Yamamoto A; Matsuzawa Y; Yokoyama S; Funahashi T; Yamamura T; Kishino B
Am J Cardiol; 1986 Jun; 57(16):29H-35H. PubMed ID: 3728307
[TBL] [Abstract][Full Text] [Related]
14. Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles.
Helve E; Tikkanen MJ
Atherosclerosis; 1988 Aug; 72(2-3):189-97. PubMed ID: 3063268
[TBL] [Abstract][Full Text] [Related]
15. Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein.
Okada T; Sumida M; Ohama T; Katayama Y; Saga A; Inui H; Kanno K; Masuda D; Koseki M; Nishida M; Sakata Y; Yamashita S
J Atheroscler Thromb; 2021 Jul; 28(7):703-715. PubMed ID: 33028763
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia.
Durrington PN; Miller JP
Atherosclerosis; 1985 May; 55(2):187-94. PubMed ID: 3890872
[TBL] [Abstract][Full Text] [Related]
17. Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia.
Kajinami K; Nishitsuji M; Takeda Y; Shimizu M; Koizumi J; Mabuchi H
Atherosclerosis; 1996 Feb; 120(1-2):181-7. PubMed ID: 8645359
[TBL] [Abstract][Full Text] [Related]
18. Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action.
Nguyen SD; Sok DE
Free Radic Res; 2003 Dec; 37(12):1319-30. PubMed ID: 14753756
[TBL] [Abstract][Full Text] [Related]
19. Biliary lipid composition in heterozygous familial hypercholesterolemia and influence of treatment with probucol.
Tanno N; Oikawa S; Koizumi M; Kotake H; Hirakawa H; Kanazawa Y; Toyota T
Dig Dis Sci; 1994 Jul; 39(7):1586-91. PubMed ID: 8026274
[TBL] [Abstract][Full Text] [Related]
20. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma.
Inazu A; Koizumi J; Kajinami K; Kiyohar T; Chichibu K; Mabuchi H
Atherosclerosis; 1999 Aug; 145(2):405-13. PubMed ID: 10488970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
